DE60020677D1 - Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln - Google Patents

Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln

Info

Publication number
DE60020677D1
DE60020677D1 DE60020677T DE60020677T DE60020677D1 DE 60020677 D1 DE60020677 D1 DE 60020677D1 DE 60020677 T DE60020677 T DE 60020677T DE 60020677 T DE60020677 T DE 60020677T DE 60020677 D1 DE60020677 D1 DE 60020677D1
Authority
DE
Germany
Prior art keywords
microparticles
emulsifying agent
oil
microemulsions
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60020677T
Other languages
English (en)
Other versions
DE60020677T2 (de
Inventor
Derek O'hagan
Gary S Ott
John Donnelly
Jina Kazzaz
Mildred Ugozzoli
Manmohan Singh
John Barackman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27382688&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60020677(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE60020677D1 publication Critical patent/DE60020677D1/de
Application granted granted Critical
Publication of DE60020677T2 publication Critical patent/DE60020677T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Colloid Chemistry (AREA)
DE60020677T 1999-02-26 2000-02-09 Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln Expired - Lifetime DE60020677T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12185899P 1999-02-26 1999-02-26
US121858P 1999-02-26
US14639199P 1999-07-29 1999-07-29
US146391P 1999-07-29
US16199799P 1999-10-28 1999-10-28
US161997P 1999-10-28
PCT/US2000/003331 WO2000050006A2 (en) 1999-02-26 2000-02-09 Microemulsions with adsorbed macromoelecules and microparticles

Publications (2)

Publication Number Publication Date
DE60020677D1 true DE60020677D1 (de) 2005-07-14
DE60020677T2 DE60020677T2 (de) 2006-05-04

Family

ID=27382688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60020677T Expired - Lifetime DE60020677T2 (de) 1999-02-26 2000-02-09 Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln

Country Status (9)

Country Link
US (4) US8206749B1 (de)
EP (3) EP2286792A1 (de)
JP (4) JP2002537102A (de)
AT (1) ATE297190T1 (de)
AU (1) AU2875700A (de)
CA (2) CA2689696C (de)
DE (1) DE60020677T2 (de)
ES (2) ES2579783T3 (de)
WO (1) WO2000050006A2 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
CA2689696C (en) 1999-02-26 2013-08-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
RU2257198C2 (ru) 2000-09-28 2005-07-27 Чирон Корпорейшн Композиции микрочастиц и способы их получения
CA2421683C (en) * 2000-09-28 2009-09-15 Chiron Corporation Microparticles for delivery of the heterologous nucleic acids
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
US6552004B1 (en) * 2000-10-30 2003-04-22 Universite De Montreal Delivery system for entrapping charged macromolecules and a method for preparing same
AU2002231336B2 (en) * 2000-12-27 2007-06-28 Surefire Medical, Inc. D/B/A Trisalus Life Sciences Immunomodulatory polynucleotides and methods of using the same
EP1420829A4 (de) 2001-08-07 2006-05-17 Dynavax Tech Corp Immunmodulierende zusammensetzungen, formulierungen sowie verfahren zu deren verwendung
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003028661A2 (en) * 2001-10-03 2003-04-10 Chiron Corporation Adjuvanted meningococcus compositions
AU2002347062B2 (en) * 2001-10-06 2008-06-26 Merial Ltd CpG formulations and related methods
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
WO2004012751A1 (ja) * 2002-08-02 2004-02-12 Sumitomo Pharmaceuticals Company, Limited 細菌細胞壁骨格成分製剤
EP1551376A4 (de) 2002-08-12 2010-10-06 Dynavax Tech Corp Immunomodulatorische zusammensetzungen, herstellungsverfahren und verwendungsverfahren dafür
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CA2511512C (en) 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
EP1622566A4 (de) * 2003-04-25 2008-06-25 Novartis Vaccines & Diagnostic Zusammensetzungen mit kationischen mikroteilchen und hcv e1e2 dna und anwendungsverfahren dafür
PL1631264T5 (pl) 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
ES2899590T3 (es) 2004-01-23 2022-03-14 Eden Research Plc Métodos de eliminación de nematodos que comprenden la aplicación de un componente terpénico
EP2338332B1 (de) 2004-05-20 2014-02-12 Eden Research Plc Hohles glukan- oder zellenwand-partikel, das eine terpenkomponente verkapselt
PL1861120T3 (pl) 2005-03-23 2016-11-30 Zastosowanie wirusa grypy i adiuwantu emulsji olej-w-wodzie do indukcji komórek t cd4+ i/lub ulepszonej odpowiedzi komórek b pamięci
WO2006110699A1 (en) * 2005-04-11 2006-10-19 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
EP1951200A2 (de) * 2005-08-09 2008-08-06 Nanobio Corporation Eine nanoemulsion enthaltende zusammensetzungen mit entzündungshemmender wirkung
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052055A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568212A (en) * 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
AU2006310246B2 (en) * 2005-11-04 2010-12-23 Seqirus UK Limited Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
JP5539649B2 (ja) 2005-12-13 2014-07-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞移植のための足場
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
SG172696A1 (en) 2006-06-12 2011-07-28 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
JP5389662B2 (ja) 2006-12-12 2014-01-15 サイトス バイオテクノロジー アーゲー 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2008241413A1 (en) * 2007-04-18 2008-10-30 The Regents Of The University Of California Protein-modified nano-droplets, compositions and methods of production
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
EP3067048B1 (de) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Zusammensetzungen zur induzierung von immunreaktionen
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2254602B1 (de) 2008-02-13 2018-11-21 President and Fellows of Harvard College Kontinuierliche zellprogrammiervorrichtungen
WO2009123480A1 (en) * 2008-04-01 2009-10-08 Virionyx Corporation Ltd Anti-infective agents and uses thereof
ES2712505T3 (es) 2008-04-17 2019-05-13 Pds Biotechnology Corp Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos
CA2721510A1 (en) * 2008-04-18 2009-10-22 Nanobio Corporation Methods for treating herpes virus infections
EP3023107A1 (de) 2008-04-21 2016-05-25 Nanobio Corporation Nanoemulsions-influenza-impfstoff
EP2293787A1 (de) 2008-04-25 2011-03-16 Nanobio Corporation Nanoemulsionen zur behandlung von pilz-, hefe- und schimmelpilzinfektionen
US20090269394A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Methods and compositions for treating onchomycosis
CA2826508C (en) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
NZ727616A (en) 2008-06-27 2018-06-29 Zoetis Services Llc Novel adjuvant compositions
WO2010036938A2 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
CA2751379C (en) 2009-02-10 2018-06-12 Novartis Ag Influenza vaccines with reduced amounts of squalene
JP6110140B2 (ja) * 2009-06-16 2017-04-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ナノエマルションワクチン
GB0913442D0 (en) * 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011014871A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
AU2013202706B2 (en) * 2009-12-03 2016-02-11 Novartis Ag Circulation of components during microfluidization and/or homogenization emulsions
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DK2356983T3 (da) * 2009-12-03 2013-03-11 Novartis Ag Cirkulation af bestanddele under homogenisering af emulsioner
DK2343052T3 (da) 2009-12-03 2013-09-02 Novartis Ag Hydrofil filtrering under fremstilling af vaccineadjuvanter
MX343410B (es) 2010-07-06 2016-11-04 Novartis Ag * Emulsiones cationicas de agua en aceite.
EP3578205A1 (de) 2010-08-06 2019-12-11 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
SG190679A1 (en) 2010-10-01 2013-07-31 Jason Schrum Engineered nucleic acids and methods of use thereof
LT2624873T (lt) 2010-10-06 2020-03-10 President And Fellows Of Harvard College Įšvirkščiami, poras sudarantys hidrogeliai, skirti medžiagų pagrindo ląstelių terapijai
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CA2833385C (en) 2011-04-28 2020-10-27 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CA2838125A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
CN103781470A (zh) 2011-07-06 2014-05-07 诺华股份有限公司 包含核酸的水包油乳液
CN103796639B (zh) 2011-07-06 2017-05-31 诺华股份有限公司 阳离子水包油乳液
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9446090B2 (en) 2012-03-23 2016-09-20 Amicrobe, Inc. Compositions and uses of antimicrobial materials with tissue-compatible properties
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6199957B2 (ja) 2012-04-16 2017-09-20 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 免疫応答を調節するためのメソポーラスシリカ組成物
RU2649365C2 (ru) * 2012-06-15 2018-04-02 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Вакцинные композиции с катионными липидами и способы применения
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP2971010B1 (de) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN109675025A (zh) 2013-09-19 2019-04-26 硕腾服务有限责任公司 油基佐剂
EP2851066A1 (de) * 2013-09-23 2015-03-25 LTS LOHMANN Therapie-Systeme AG Fixierung von Impfstoffformulierungen auf Einrichtungen zur epidermalen Immunisierung durch ölige Adjuvantien
EP3052106A4 (de) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynukleotide zur codierung immunmodulierender polypeptide
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
EP3137105A4 (de) 2014-04-30 2017-12-27 President and Fellows of Harvard College Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
EP3169693B1 (de) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimäre polynukleotide
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
EP3204039B1 (de) * 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen
US10478487B2 (en) 2015-01-16 2019-11-19 Zoetis Services Llc Foot-and-mouth disease vaccine
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
CN107708756A (zh) 2015-04-10 2018-02-16 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
US11123740B2 (en) 2015-06-29 2021-09-21 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis
ES2937963T3 (es) 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
EP3364950A4 (de) 2015-10-22 2019-10-23 ModernaTX, Inc. Impfstoffe gegen tropenkrankheiten
CN117731769A (zh) 2015-10-22 2024-03-22 摩登纳特斯有限公司 用于水痘带状疱疹病毒(vzv)的核酸疫苗
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
CA3007955A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
US10799463B2 (en) 2015-12-22 2020-10-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
HRP20220525T1 (hr) 2015-12-23 2022-05-27 Modernatx, Inc. Postupci uporabe polinukleotida koji kodiraju ligand ox40
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
EP3411475A4 (de) 2016-02-06 2019-09-11 President and Fellows of Harvard College Rekapitulation der hämatopoietischen nische zur wiederherstellung der immunität
US9949915B2 (en) 2016-06-10 2018-04-24 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
CN110740813B (zh) 2016-11-28 2022-06-03 亚利桑那州立大学董事会 涉及连续流动液滴反应的***和方法
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
EP3609534A4 (de) 2017-03-15 2021-01-13 ModernaTX, Inc. Influenza-virus-impfstoff mit breitem spektrum
ES2940259T3 (es) 2017-03-15 2023-05-04 Modernatx Inc Compuesto y composiciones para la administración intracelular de agentes terapéuticos
CA3056133A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
AU2018249552A1 (en) 2017-04-06 2019-10-31 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
EP3681514A4 (de) 2017-09-14 2021-07-14 ModernaTX, Inc. Rna-vakzine gegen zika-virus
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
WO2019169370A1 (en) * 2018-03-02 2019-09-06 University Of The Sciences Polymer compositions for storage and release of polypeptides
WO2019195197A1 (en) 2018-04-02 2019-10-10 Dropworks, Inc. Systems and methods for serial flow emulsion processes
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2020246584A1 (ja) * 2019-06-06 2020-12-10 デンカ株式会社 ペプチド核酸を基盤としたアジュバント
EP4031524A1 (de) 2019-09-19 2022-07-27 ModernaTX, Inc. Lipidverbindungen mit verzweigtem ende und zusammensetzungen zur intrazellulären abgabe therapeutischer mittel
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
CN111658611B (zh) * 2020-04-13 2021-06-01 四川大学 一种基于微乳的疫苗递送***及其制备方法和应用
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA583561A (en) 1959-09-22 H. Edgerton William Therapeutically valuable esters and methods for obtaining the same
US1565298A (en) 1925-12-15 Stop check announcing device for adding machines
US1573698A (en) 1922-06-21 1926-02-16 Union Carbide & Carbon Res Lab Denatured alcohol
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
FR1317586A (de) 1961-03-17 1963-05-08
BE634667A (de) 1962-07-11
BE755269A (fr) 1969-08-25 1971-02-01 Westinghouse Electric Corp Systeme de regulation d'epaisseur du produit lamine sortant d'un laminoir
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4772466A (en) 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5324513A (en) 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
EP0628633B1 (de) 1984-04-06 2003-01-08 Chiron Corporation Rekombinanter Herpes Simplex gB-gD-Impfstoff
US5098704A (en) 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US4689225A (en) 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4826957A (en) 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
ES2061500T5 (es) 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
DK341386D0 (da) 1986-07-18 1986-07-18 Voetman Karin Glassau Fremgangsmaade og apparat til oprulning af flade dejstykker, f.eks. til roulader
WO1988002634A1 (en) 1986-10-20 1988-04-21 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
DE3855807T2 (de) 1987-11-03 1997-06-12 Syntex (U.S.A.) Inc., Palo Alto, Calif. Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
NZ227011A (en) 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
DE68929478T2 (de) 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
DK0398748T3 (da) 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
CH679207A5 (de) 1989-07-28 1992-01-15 Debiopharm Sa
AU654824B2 (en) * 1990-06-29 1994-11-24 Chiron Corporation Vaccine compositions containing liposomes
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CA2150803C (en) 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JPH0827018A (ja) 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
WO1996040961A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
US5814516A (en) 1995-10-13 1998-09-29 Lockheed Martin Energy Systems, Inc. Surface enhanced Raman gene probe and methods thereof
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
GB9608803D0 (en) 1996-04-27 1996-07-03 Univ Newcastle Mitochondrial dna defects
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US5821060A (en) 1996-08-02 1998-10-13 Atom Sciences, Inc. DNA sequencing, mapping, and diagnostic processes using hybridization chips and unlabeled DNA
WO1998015648A1 (en) 1996-10-04 1998-04-16 Dako A/S Novel probes for the detection of mycobacteria
DE19640974A1 (de) 1996-10-04 1998-04-16 Bayer Ag Bausteine für DNA/PNA-Cooligomere
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
GB9621367D0 (en) 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
EP0939762A2 (de) 1996-11-05 1999-09-08 Clinical Micro Sensors Elektrode die durch leitende oligomere zur nukleinsäuren gebunden sind
US5800999A (en) 1996-12-16 1998-09-01 Tropix, Inc. Dioxetane-precursor-labeled probes and detection assays employing the same
EP0991403B1 (de) 1997-01-30 2003-04-02 Chiron Corporation Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
KR19980067138A (ko) * 1997-01-31 1998-10-15 박원훈 유전자 또는 생물학적 활성 약물을 세포내로 효과적으로 전달하는 지방 유제 및 그것의 제조방법
CA2228875A1 (en) 1997-02-08 1998-08-08 Boehringer Mannheim Gmbh A method for the preparation of nucleic acid binding compound
US5962230A (en) 1997-02-13 1999-10-05 The University Of Connecticut Diagnosis and treatment of glaucoma
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
DE19712530A1 (de) 1997-03-25 1998-10-01 Boehringer Mannheim Gmbh Neue Monomerbausteine zur Markierung von peptidischen Nukleinsäuren
US6086900A (en) 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
CA2293489C (en) 1997-06-06 2009-09-29 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
ATE321882T1 (de) * 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
JP2002509545A (ja) * 1997-07-08 2002-03-26 カイロン コーポレイション Ｄｎａワクチンを伴うサブミクロン水中油型エマルジョンの使用
SE9702776D0 (sv) * 1997-07-22 1997-07-22 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
JP4918188B2 (ja) 1997-12-16 2012-04-18 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
US6045816A (en) * 1998-06-17 2000-04-04 Isp Investments Inc. Water-based microemulsion of a pyrethroid
ATE321535T1 (de) 1998-07-29 2006-04-15 Chiron Corp Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
CA2689696C (en) 1999-02-26 2013-08-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
KR100701569B1 (ko) 2006-07-10 2007-03-29 주식회사 경동나비엔 응축방지를 위한 저장식 보일러의 열교환기 구조
EP2019117A1 (de) 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimiertes Reinigungsverfahren für rekombinantes Wachstumsfaktorprotein
CN102792149B (zh) 2010-03-12 2015-05-20 柯尼卡美能达先进多层薄膜株式会社 分子间相互作用的检测方法及其检测装置
JP6136343B2 (ja) 2012-06-12 2017-05-31 株式会社リコー 情報処理システム、情報処理方法、プログラム、及び記録媒体
AT514720B1 (de) 2013-08-30 2016-03-15 Blum Gmbh Julius Stellvorrichtung
CN104683216B (zh) 2013-11-29 2019-04-12 腾讯科技（深圳）有限公司 客服信息的转发方法及装置、客服***
JP6287387B2 (ja) 2014-03-12 2018-03-07 株式会社リコー 液滴吐出装置の液体粘度検出方法、液滴吐出装置の制御方法、液滴吐出装置、及び液滴吐出装置の液体粘度を検出する回路
FR3030069B1 (fr) 2014-12-16 2020-03-20 Zrc Geneve Sa Montre a lunette tournante
KR102354328B1 (ko) 2015-09-22 2022-01-21 삼성전자주식회사 영상 표시 장치 및 그 동작 방법
US9680022B1 (en) 2016-07-12 2017-06-13 United Microelectronics Corp. Semiconductor device having silicon-germanium layer on fin and method for manufacturing the same

Also Published As

Publication number Publication date
EP1574210B1 (de) 2016-04-06
US8206749B1 (en) 2012-06-26
ES2242604T3 (es) 2005-11-16
US8734832B2 (en) 2014-05-27
EP1156781A2 (de) 2001-11-28
JP2002537102A (ja) 2002-11-05
WO2000050006A2 (en) 2000-08-31
US8309139B2 (en) 2012-11-13
ATE297190T1 (de) 2005-06-15
EP1574210A2 (de) 2005-09-14
EP1156781B1 (de) 2005-06-08
US8771747B2 (en) 2014-07-08
WO2000050006A3 (en) 2001-01-18
CA2363141C (en) 2010-04-06
CA2689696C (en) 2013-08-06
EP2286792A1 (de) 2011-02-23
JP2016172767A (ja) 2016-09-29
AU2875700A (en) 2000-09-14
US20130195898A1 (en) 2013-08-01
EP1574210A3 (de) 2007-02-21
JP6073053B2 (ja) 2017-02-01
JP2012017344A (ja) 2012-01-26
JP2014169323A (ja) 2014-09-18
US20070116709A1 (en) 2007-05-24
CA2363141A1 (en) 2000-08-31
ES2579783T3 (es) 2016-08-16
DE60020677T2 (de) 2006-05-04
US20130195923A1 (en) 2013-08-01
CA2689696A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
ATE297190T1 (de) Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
DK1322287T3 (da) Mikropartikler til administration af heterologe nukleinsyrer
DE69937571D1 (de) Mutiertes cholera holotoxin als hilfsmittel
CY1107326T1 (el) Μικροσωματιδια με απορροφητικες επιφανειες, μεθοδοι κατασκευης αυτων και χρησεις αυτων
WO2007006939A3 (fr) Emulsion immuno-adjuvante thermoreversible
MY133780A (en) Vaccine composition
HK1121382A1 (en) Adjuvant compositions for enhancing immune responses to polynucleotide- based vaccines
WO2001060402A3 (en) Proteosome influenza vaccine
WO2004030608A3 (en) Nanoemulsion vaccines
EP1741782A9 (de) Durch Mage Minigene kodierte immunogene Polypeptide und ihre Verwendungen
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
LU91485I2 (fr) Vaccin adjuvant grippal dans lequel l'adjuvant estune émulsion huile-dans-eau comprenant du squalèn e, du DL-a-tocophérol et du polysorbate 80
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
IS7601A (is) Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum
ZA964894B (en) Immunological combination compositions and methods.
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
JP2001131087A5 (de)
WO2001062283A3 (en) Mucosal adjuvant formulation
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
WO2003051288A3 (en) Mycobacterial vaccine
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
AU2003296592A8 (en) Antigen-complexes
WO2000069458A3 (en) Adjuvant combinations for immunization composition and vaccines
WO2001049320A3 (en) Use of hemicellulose microparticles as vaccine adjuvant

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US